EXACT Sciences Co. (NASDAQ:EXAS) was the target of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 27,657,649 shares, a decline of 9.0% from the April 28th total of 30,407,001 shares. Approximately 25.4% of the company’s stock are sold short. Based on an average daily trading volume, of 4,910,228 shares, the days-to-cover ratio is presently 5.6 days.

Several analysts recently commented on the stock. Jefferies Group LLC reiterated a “buy” rating and issued a $35.00 price target on shares of EXACT Sciences in a research report on Tuesday, May 16th. Vetr upgraded shares of EXACT Sciences from a “buy” rating to a “strong-buy” rating and set a $36.13 price target for the company in a research report on Tuesday, May 16th. Benchmark Co. upgraded shares of EXACT Sciences from a “hold” rating to a “buy” rating and upped their price target for the company from $17.00 to $27.00 in a research report on Tuesday, February 21st. Cowen and Company upped their price target on shares of EXACT Sciences from $40.00 to $45.00 and gave the company an “outperform” rating in a research report on Monday, May 15th. Finally, Zacks Investment Research downgraded shares of EXACT Sciences from a “buy” rating to a “hold” rating in a research report on Friday, February 24th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and twelve have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $27.41.

EXACT Sciences (NASDAQ:EXAS) opened at 33.32 on Friday. The stock’s 50 day moving average is $29.17 and its 200-day moving average is $20.92. The firm’s market capitalization is $3.70 billion. EXACT Sciences has a 1-year low of $6.39 and a 1-year high of $36.14.

EXACT Sciences (NASDAQ:EXAS) last posted its earnings results on Thursday, April 27th. The medical research company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.09. The company had revenue of $48.36 million for the quarter, compared to analysts’ expectations of $37.38 million. EXACT Sciences had a negative return on equity of 55.44% and a negative net margin of 216.45%. The firm’s quarterly revenue was up 225.9% compared to the same quarter last year. During the same period last year, the business posted ($0.49) earnings per share. Equities research analysts forecast that EXACT Sciences will post ($1.35) EPS for the current year.

In related news, COO Maneesh Arora sold 5,574 shares of the company’s stock in a transaction on Monday, March 13th. The shares were sold at an average price of $21.16, for a total value of $117,945.84. Following the completion of the sale, the chief operating officer now owns 556,339 shares in the company, valued at approximately $11,772,133.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP D Scott Coward sold 1,543 shares of the company’s stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $23.74, for a total transaction of $36,630.82. Following the completion of the sale, the senior vice president now owns 55,478 shares of the company’s stock, valued at approximately $1,317,047.72. The disclosure for this sale can be found here. Insiders have sold a total of 47,987 shares of company stock valued at $1,028,453 in the last 90 days. Insiders own 5.60% of the company’s stock.

Large investors have recently bought and sold shares of the stock. FIL Ltd boosted its stake in EXACT Sciences by 397.3% in the fourth quarter. FIL Ltd now owns 660,686 shares of the medical research company’s stock worth $8,827,000 after buying an additional 527,826 shares during the last quarter. Columbia Wanger Asset Management LLC boosted its stake in shares of EXACT Sciences by 54.7% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 864,133 shares of the medical research company’s stock worth $11,545,000 after buying an additional 305,699 shares in the last quarter. Raymond James Financial Services Advisors Inc. bought a new stake in shares of EXACT Sciences during the fourth quarter worth $192,000. State Street Corp boosted its stake in shares of EXACT Sciences by 11.7% in the fourth quarter. State Street Corp now owns 5,554,992 shares of the medical research company’s stock worth $74,211,000 after buying an additional 582,802 shares in the last quarter. Finally, Artemis Investment Management LLP boosted its stake in shares of EXACT Sciences by 94.2% in the fourth quarter. Artemis Investment Management LLP now owns 164,870 shares of the medical research company’s stock worth $2,203,000 after buying an additional 79,985 shares in the last quarter. Institutional investors own 86.54% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Short Interest in EXACT Sciences Co. (EXAS) Drops By 9.0%” was first published by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/05/27/short-interest-in-exact-sciences-co-exas-drops-by-9-0.html.

EXACT Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

12 Month Chart for NASDAQ:EXAS

Receive News & Ratings for EXACT Sciences Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences Co. and related companies with MarketBeat.com's FREE daily email newsletter.